HC Wainwright Cuts Vigil Neuroscience (NASDAQ:VIGL) Price Target to $14.00

Vigil Neuroscience (NASDAQ:VIGL) had its price target trimmed by HC Wainwright from $17.00 to $14.00 in a report published on Friday,Benzinga reports. The firm currently has a buy rating on the stock.

VIGL has been the subject of several other research reports. Guggenheim restated a “buy” rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. JMP Securities reiterated a “market outperform” rating and issued a $22.00 price objective on shares of Vigil Neuroscience in a research report on Tuesday, November 26th. Finally, William Blair started coverage on Vigil Neuroscience in a research report on Wednesday, December 4th. They issued an “outperform” rating for the company. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $16.25.

Vigil Neuroscience Stock Down 4.3 %

Shares of NASDAQ:VIGL opened at $2.02 on Friday. The business has a 50 day moving average price of $2.34 and a 200 day moving average price of $2.78. Vigil Neuroscience has a twelve month low of $1.49 and a twelve month high of $6.06. The company has a market cap of $82.58 million, a price-to-earnings ratio of -0.98 and a beta of 1.82.

Vigil Neuroscience (NASDAQ:VIGL) last announced its earnings results on Thursday, March 13th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.08). Analysts anticipate that Vigil Neuroscience will post -2.07 EPS for the current year.

Institutional Trading of Vigil Neuroscience

A number of hedge funds have recently modified their holdings of the company. abrdn plc raised its holdings in shares of Vigil Neuroscience by 124.9% in the 4th quarter. abrdn plc now owns 528,472 shares of the company’s stock worth $898,000 after buying an additional 293,461 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Vigil Neuroscience by 41.9% in the 3rd quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock worth $769,000 after buying an additional 66,712 shares in the last quarter. Verition Fund Management LLC acquired a new position in shares of Vigil Neuroscience in the 3rd quarter worth approximately $442,000. Walleye Capital LLC raised its holdings in shares of Vigil Neuroscience by 334.4% in the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock worth $407,000 after buying an additional 92,217 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its holdings in shares of Vigil Neuroscience by 7.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company’s stock worth $5,440,000 after buying an additional 115,000 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.